Millipore Sigma Vibrant Logo

PF082 VEGFR1, Human, Recombinant, S. frugiperda

VEGFR1, Human, Recombinant, S. frugiperda: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: Vascular Endothelial Growth Factor Receptor-1, Flt-1, EMRK2

View This Product on Sigma-Aldrich
PF082
価格＆在庫状況を照会

概要

Replacement Information

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
PF082-50UGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 50 μg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewRecombinant, human VEGFR-1 expressed in S. frugiperda insect cells. Plays an important role in angiogenesis. Upon binding to VEGF, the receptor undergoes dimerization and is activated, leading to downstream signaling.
      Catalogue NumberPF082
      Brand Family Calbiochem®
      SynonymsVascular Endothelial Growth Factor Receptor-1, Flt-1, EMRK2
      References
      ReferencesHuang, K., et al. 2001. Int. J. Cell Biol. 33, 315.
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Conn, G., et al. 1990. PNAS 87, 1323.
      Shibuya, M., et al. 1990. Oncogene 5, 519.
      Product Information
      FormLyophilized
      FormulationLyophilized from sterile-filtered PBS, 300 mM NaCl, 50 µg BSA/µg of cytokine.
      Quality LevelMQ100
      Applications
      日付設定エラー。 ページレット<collection_feature_application_id-PROLIF>が見つかりません
      Biological Information
      Biological activityEC₅₀ of 15-30 ng/ml in a cell proliferation assay using human umbilical vein endothelial cells
      Purity≥90% by SDS-PAGE
      Species Reactivity
      • Human
      Physicochemical Information
      ContaminantsEndotoxin: ≤1 EU/µg cytokine
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      PF082-50UGCN 04055977207484

      Documentation

      VEGFR1, Human, Recombinant, S. frugiperda (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      VEGFR1, Human, Recombinant, S. frugiperda 試験成績書（CoA）

      タイトルロット番号
      PF082

      参考資料

      参考資料の概要
      Huang, K., et al. 2001. Int. J. Cell Biol. 33, 315.
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Conn, G., et al. 1990. PNAS 87, 1323.
      Shibuya, M., et al. 1990. Oncogene 5, 519.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision16-September-2008 RFH
      SynonymsVascular Endothelial Growth Factor Receptor-1, Flt-1, EMRK2
      DescriptionRecombinant, human VEGFR-1 expressed in S. frugiperda insect cells. The disulfide linked dimeric recombinant protein contains two polypeptides of 905 amino acids long with a predicted monomeric molecular mass of ~100 kDa. As a result of glycosylation, the monomer migrates as a ~123 kDa protein in SDS-PAGE. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a secreted heparin binding cytokine expressed in tumor and animal cells. VEGF has been implicated in the control of angiogenesis due to its selective mitogenic stimulation of vascular endothelial cells and enhancement of vascular permeability. VEGF is a ~34-50 kDa dimer of two identical disulfide-linked subunits existing in four molecular species; 121, 165, 189, and 206 amino acid residues long, arising from alternative splicing of a single gene. VEGF binds to two receptor tyrosine kinases, Flt-1 (VEGFR1) and KDR/Flk-1 (VEGFR2) found almost exclusively on human endothelial cells. Flt-1 binds VEGF and a new VEGF-related ligand, placenta growth factor (PIGF) but KDR/Flk-1 binds only VEGF. The cDNA encoding the soluble truncated form of Flt-1 cloned from a human endothelial cell library encodes the 6 N-terminal IgG-like extracellular ligand-binding domain but does not encode the transmembrane spanning region and intracellular tyrosine kinase domains. The recombinant soluble receptor binds avidly to VEGF and is a potent VEGF antagonist. Recently, a third VEGF receptor was identified and cloned from tumor cells. This VEGF receptor is isoform-specific, binding VEGF165 but not VEGF121. Studies indicate that this VEGF receptor (VEGF165R) is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance.
      Specieshuman
      FormLyophilized
      FormulationLyophilized from sterile-filtered PBS, 300 mM NaCl, 50 µg BSA/µg of cytokine.
      Purity≥90% by SDS-PAGE
      ContaminantsEndotoxin: ≤1 EU/µg cytokine
      Biological activityEC₅₀ of 15-30 ng/ml in a cell proliferation assay using human umbilical vein endothelial cells
      SolubilityReconstitute to ≥10 µg/ml with sterile PBS containing ≥0.1% HSA or BSA. It is recommended that the protein be titrated for optimal results in individual systems.
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesHuang, K., et al. 2001. Int. J. Cell Biol. 33, 315.
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Conn, G., et al. 1990. PNAS 87, 1323.
      Shibuya, M., et al. 1990. Oncogene 5, 519.